MediWound (MDWD) Competitors

$16.58 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$16.30 -0.28 (-1.68%)

As of 05/22/2026 07:00 PM Eastern

MDWD vs. KURA, DRUG, EVMN, ETON, and AMPH

Should you buy MediWound stock or one of its competitors? MarketBeat compares MediWound with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediWound include Kura Oncology (KURA), Bright Minds Biosciences (DRUG), Evommune (EVMN), Eton Pharmaceuticals (ETON), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.

How does MediWound compare to Kura Oncology?

MediWound (NASDAQ:MDWD) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

MediWound has higher earnings, but lower revenue than Kura Oncology. MediWound is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	12.56	-$23.88M	-$2.10	N/A
Kura Oncology	$67.48M	14.80	-$278.67M	-$3.35	N/A

MediWound presently has a consensus price target of $35.00, indicating a potential upside of 111.10%. Kura Oncology has a consensus price target of $26.38, indicating a potential upside of 134.44%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

MediWound has a net margin of -140.80% compared to Kura Oncology's net margin of -411.19%. MediWound's return on equity of -65.79% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-140.80%	-65.79%	-30.16%
Kura Oncology	-411.19%	-141.95%	-43.28%

MediWound has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

46.8% of MediWound shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Kura Oncology had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for MediWound. Kura Oncology's average media sentiment score of 0.30 beat MediWound's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kura Oncology beats MediWound on 9 of the 16 factors compared between the two stocks.

How does MediWound compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

In the previous week, Bright Minds Biosciences had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 1 mentions for MediWound. Bright Minds Biosciences' average media sentiment score of 2.04 beat MediWound's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bright Minds Biosciences has a beta of -5.35, suggesting that its stock price is 635% less volatile than the broader market. Comparatively, MediWound has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bright Minds Biosciences has higher earnings, but lower revenue than MediWound. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
MediWound	$16.96M	12.56	-$23.88M	-$2.10	N/A

Bright Minds Biosciences presently has a consensus target price of $143.83, indicating a potential upside of 72.26%. MediWound has a consensus target price of $35.00, indicating a potential upside of 111.10%. Given MediWound's higher possible upside, analysts plainly believe MediWound is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Bright Minds Biosciences has a net margin of 0.00% compared to MediWound's net margin of -140.80%. Bright Minds Biosciences' return on equity of -20.58% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
MediWound	-140.80%	-65.79%	-30.16%

Summary

Bright Minds Biosciences beats MediWound on 9 of the 15 factors compared between the two stocks.

How does MediWound compare to Evommune?

MediWound (NASDAQ:MDWD) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Evommune has a net margin of 0.00% compared to MediWound's net margin of -140.80%. Evommune's return on equity of 0.00% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-140.80%	-65.79%	-30.16%
Evommune	N/A	N/A	N/A

In the previous week, MediWound and MediWound both had 1 articles in the media. MediWound's average media sentiment score of 0.00 equaled Evommune'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MediWound has higher revenue and earnings than Evommune. MediWound is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	12.56	-$23.88M	-$2.10	N/A
Evommune	$13M	63.00	-$68.87M	-$9.50	N/A

MediWound presently has a consensus target price of $35.00, suggesting a potential upside of 111.10%. Evommune has a consensus target price of $49.25, suggesting a potential upside of 116.62%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

46.8% of MediWound shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Evommune beats MediWound on 9 of the 14 factors compared between the two stocks.

How does MediWound compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Eton Pharmaceuticals currently has a consensus price target of $41.00, suggesting a potential upside of 25.81%. MediWound has a consensus price target of $35.00, suggesting a potential upside of 111.10%. Given MediWound's higher possible upside, analysts plainly believe MediWound is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Eton Pharmaceuticals has a net margin of -1.70% compared to MediWound's net margin of -140.80%. Eton Pharmaceuticals' return on equity of -5.68% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
MediWound	-140.80%	-65.79%	-30.16%

Eton Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, MediWound has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than MediWound. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for MediWound. Eton Pharmaceuticals' average media sentiment score of 0.25 beat MediWound's score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eton Pharmaceuticals has higher revenue and earnings than MediWound. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	11.16	-$4.60M	-$0.07	N/A
MediWound	$16.96M	12.56	-$23.88M	-$2.10	N/A

Summary

Eton Pharmaceuticals beats MediWound on 12 of the 16 factors compared between the two stocks.

How does MediWound compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 1 articles in the media. Amphastar Pharmaceuticals' average media sentiment score of 0.46 beat MediWound's score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.13	$98.09M	$1.66	11.09
MediWound	$16.96M	12.56	-$23.88M	-$2.10	N/A

Amphastar Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, MediWound has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Amphastar Pharmaceuticals currently has a consensus target price of $24.50, indicating a potential upside of 33.08%. MediWound has a consensus target price of $35.00, indicating a potential upside of 111.10%. Given MediWound's stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Amphastar Pharmaceuticals has a net margin of 11.00% compared to MediWound's net margin of -140.80%. Amphastar Pharmaceuticals' return on equity of 15.12% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
MediWound	-140.80%	-65.79%	-30.16%

Summary

Amphastar Pharmaceuticals beats MediWound on 11 of the 15 factors compared between the two stocks.

Get MediWound News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDWD vs. The Competition

Export

Metric	MediWound	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$213.09M	$3.03B	$6.43B	$12.32B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-7.90	17.79	21.00	25.66
Price / Sales	12.56	784.72	615.84	111.99
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	4.88	5.86	10.37	7.14
Net Income	-$23.88M	$74.99M	$3.57B	$335.98M
7 Day Performance	1.10%	2.55%	6.00%	3.56%
1 Month Performance	-0.84%	-3.05%	3.51%	2.54%
1 Year Performance	-18.61%	34.38%	34.12%	35.05%

MediWound Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDWD MediWound	1.641 of 5 stars	$16.58 flat	$35.00 +111.1%	-18.6%	$213.09M	$16.96M	N/A	80	Upcoming Earnings
KURA Kura Oncology	2.4394 of 5 stars	$9.68 +1.8%	$26.38 +172.5%	+99.5%	$844.13M	$67.48M	N/A	130
DRUG Bright Minds Biosciences	3.2319 of 5 stars	$84.65 -2.2%	$128.60 +51.9%	+187.8%	$842.32M	N/A	N/A	N/A	Positive News Earnings Report
EVMN Evommune	2.8298 of 5 stars	$22.68 -2.3%	$49.25 +117.1%	N/A	$835.99M	$13M	N/A	45	Gap Up
ETON Eton Pharmaceuticals	4.0109 of 5 stars	$29.71 -0.4%	$39.33 +32.4%	+64.5%	$816.42M	$79.95M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDWD) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediWound (MDWD) Competitors

MDWD vs. KURA, DRUG, EVMN, ETON, and AMPH

How does MediWound compare to Kura Oncology?

Summary

How does MediWound compare to Bright Minds Biosciences?

Summary

How does MediWound compare to Evommune?

Summary

How does MediWound compare to Eton Pharmaceuticals?

Summary

How does MediWound compare to Amphastar Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediWound (MDWD) Competitors

MDWD vs. KURA, DRUG, EVMN, ETON, and AMPH

How does MediWound compare to Kura Oncology?

Which has higher valuation and earnings, MDWD or KURA?

Do analysts rate MDWD or KURA?

Is MDWD or KURA more profitable?

Which has more volatility and risk, MDWD or KURA?

Do insiders & institutionals believe in MDWD or KURA?

Does the media prefer MDWD or KURA?

Summary

How does MediWound compare to Bright Minds Biosciences?

Does the media refer more to DRUG or MDWD?

Which has more volatility & risk, DRUG or MDWD?

Do institutionals & insiders have more ownership in DRUG or MDWD?

Which has higher valuation and earnings, DRUG or MDWD?

Do analysts recommend DRUG or MDWD?

Is DRUG or MDWD more profitable?

Summary

How does MediWound compare to Evommune?

Is MDWD or EVMN more profitable?

Does the media favor MDWD or EVMN?

Which has preferable valuation and earnings, MDWD or EVMN?

Do analysts recommend MDWD or EVMN?

Do institutionals and insiders hold more shares of MDWD or EVMN?

Summary

How does MediWound compare to Eton Pharmaceuticals?

Do insiders & institutionals hold more shares of ETON or MDWD?

Do analysts prefer ETON or MDWD?

Is ETON or MDWD more profitable?

Which has more risk & volatility, ETON or MDWD?

Does the media refer more to ETON or MDWD?

Which has higher earnings and valuation, ETON or MDWD?

Summary

How does MediWound compare to Amphastar Pharmaceuticals?

Does the media prefer AMPH or MDWD?

Do insiders and institutionals have more ownership in AMPH or MDWD?

Which has better valuation and earnings, AMPH or MDWD?

Which has more risk and volatility, AMPH or MDWD?

Do analysts prefer AMPH or MDWD?

Is AMPH or MDWD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools